论文部分内容阅读
目前原发性高血压(高血压)的治疗主张小剂量联合用药,以达到理想的降压效果。缬沙坦是较理想的新型抗高血压药,它通过竞争性拮抗1型血管紧张素Ⅱ受体而发挥作用,其单用降压效果和血管紧张素转化酶抑制剂(ACEI)相当,与氯沙坦的疗效相近。2003年5月～2004年12月,我们用缬沙坦联用其它抗高血压药物治疗高血压60例,旨在比较缬沙坦和蒙诺单用、联用氢氯噻嗪、联用氢氯噻嗪和非洛地平缓解释剂(波依定)的防压效果和不良反应。现将结果报告如下。
The current treatment of essential hypertension (high blood pressure) advocates low-dose combination therapy, in order to achieve the desired antihypertensive effect. Valsartan is an ideal new antihypertensive drug that acts by competitively antagonizing type 1 angiotensin II receptor. Its single antihypertensive effect is comparable to that of angiotensin-converting enzyme inhibitor (ACEI), and The effect of losartan is similar. May 2003 to December 2004, we used valsartan combined with other antihypertensive drugs in the treatment of hypertension in 60 cases, designed to compare valsartan and Monel alone, combined with hydrochlorothiazide, hydrochlorothiazide and hydrochlorothiazide in combination Antihypertensive effect of gentamycin (doxepin) and adverse reactions. The results reported below.